TRANSLOCATION OF ULTRAFINE INSOLUBLE IRIDIUM PARTICLES FROM LUNG EPITHELIUM TO EXTRAPULMONARY ORGANS IS SIZE DEPENDENT BUT VERY LOW

By W. Kreyling, M. Semmler, F. Erbe, Paula Mayer, S. Takenaka, Holger Schulz, G. Oberdörster, A. Ziesenis. Journal of Toxicology and Environmental Health, Part A, 2002

979 citations recorded by the source corpus.

Subfields: Environmental Engineering, Health, Toxicology and Mutagenesis, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0a0311f41a72a93fc6f592328ba8d6985356e98a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Environmental Engineering

1. G. Oberdörster
2. W. Kreyling
3. Vicki Stone
4. Ken Donaldson
5. Paul Borm
6. W. D. De Jong
7. Andrew D. Maynard

In Health, Toxicology and Mutagenesis

1. G. Oberdörster
2. W. D. De Jong
3. Paul Borm
4. Andrew D. Maynard
5. K. Robbie
6. I. Pacheco
7. C. Buzea
8. W. Kreyling

In Pulmonary and Respiratory Medicine

1. W. Kreyling
2. K. Robbie
3. I. Pacheco
4. C. Buzea
5. Vicki Stone
6. W. Macnee
7. Ken Donaldson
8. Paul Borm

Citations in the corpus

• EXTRAPULMONARY TRANSLOCATION OF ULTRAFINE CARBON PARTICLES FOLLOWING WHOLE-BODY INHALATION EXPOSURE OF RATS (2002, methodology): “In contrast, the aforementioned studies by Kanapilly and Diel (1980) and by Kreyling et al. (2002) with ultrafine radioactive metal particles do not show significant translocation from the GI tract to other organs via the blood circulation; nor do these studies show significant translocation of…”
• Emerging trends of nanoparticles application in food technology: Safety paradigms (2009, background): “In this regard, studies with C60 fullerenes in rats showed that 98% of it is eliminated through faeces when given orally, while more than 70% is retained in the liver upon intravenous administration (Yamago et al. 1995; Kreyling et al. 2002).”
• Drug delivery and nanoparticles: Applications and hazards (2008, background): “In some studies translocation has been rather minimal (Kreyling et al 2002; Takenaka et al 2006).”
• Adverse cardiovascular effects of air pollution (2009, background): “Translocation of inhaled nanoparticles across the alveolar–blood barrier has been demonstrated in animal studies for a range of nanoparticles delivered by inhalation or instillation”
• Assessing exposure to airborne nanomaterials: Current abilities and future requirements (2007, background): “Recent studies on particle translocation within the body have further indicated a size-dependency on the likelihood of deposited particles moving from the respiratory system to other organs (Kreyling et al. 2002; Oberdörster et al. 2004; Elder et al. 2006).”
• Comparison of four mobility particle sizers with different time resolution for stationary exposure measurements (2009, background): “Although attempts have been made to produce reference particle number concentrations ( Koch et al. 2008 ), as of now no standard method has been agreed upon for the provision of reference number concentrations.”
• Nanomaterials and nanoparticles: Sources and toxicity (2007, background): “les are internalized not only by professional phagocytes such as alveolar macrophages [30], [145], [228], but by various types of cells, including endothelial cells [230], pulmonary epithelium [142], [231, 232, 233, 234, 235, 236], gastrointestinal epithelium [204], red blood cells [203], [237], pla”
• Toxicology of nanoparticles: A historical perspective (2007, background): “For example, results of state-of-the-art retention studies with inhaled radioactive iridium nanoparticles showing less than 1% translocation from lung deposits to other organs (Kreyling et al. 2003; Semmler et al. 2004) or of more than 10% of deposited Mn-oxide nanoparticles on the nasal olfactory m”